1. Signaling Pathways
  2. Epigenetics
  3. TET Protein
  4. TET3 Isoform

TET3

TET3 (ten-eleven translocation 3) is an Fe(II)/α-ketoglutarate-dependent dioxygenase that catalyzes the iterative oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC), thereby contributing to active DNA demethylation and epigenetic regulation[1]. TET3 participates in biological processes linked to zygote formation, embryogenesis, neural function, and genome-wide methylation turnover through pathways coupled to thymine-DNA glycosylase-mediated base excision repair[1]. Mechanistically, TET3-mediated oxidation products, particularly 5fC and 5caC, can be removed and restored to unmethylated cytosine, enabling dynamic control of gene expression programs[1]. In developmental and disease-relevant contexts, dysregulation of TET family activity has been associated with multiple pathological states, highlighting the importance of TET3-dependent epigenetic homeostasis[1]. Compared with the related isoform TET2, TET3 contains an N-terminal CXXC DNA-binding domain, which directly contributes to chromatin targeting and substrate recognition[1][2]. Furthermore, full-length TET3 exhibits preferential binding of its CXXC domain to 5caC-containing CpG sequences, indicating a distinctive capacity to recognize products of its own catalytic pathway and potentially influence locus-specific demethylation events[2]. TET3 exists as multiple isoforms, including full-length and shorter variants, providing additional regulatory diversity in different cellular contexts[2]. For experimental applications, modulation of TET activity and analysis of TET3-dependent DNA hydroxymethylation are widely used to investigate epigenetic remodeling, developmental biology, and neurobiology-related mechanisms[1][2].

TET3 Related Products (1):

Cat. No. Product Name Effect Purity
  • HY-402410
    TETi76
    Inhibitor
    TETi76 is an orally active TET family inhibitor with IC50 values ??of 1.5, 9.4 and 8.8 μM for TET1, TET2 and TET3, respectively. TETi76 competitively binds to the active site of TET enzymes, reduces cytosine hydroxymethylation and restricts clonal growth of TET2 mutants in vitro and in vivo, but does not affect the growth of normal hematopoietic precursor cells. TETi76 can be used for leukemia research.